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HIGHLIGHTS   
• Electrophysiology probes Alzheimer’s effects on neurons/networks  
• It also probes drug effects on neurons/networks  
• Electrophysiology biomarkers measure channelopathy and synaptic neurotransmission  
• They also measure neural network dynamics, synchronization, and connectivity 
•  Spatial scale ranges from microscopic (m) to macroscopic (cm) measures  
• Temporal scale ranges from microseconds to hours (e.g., sleep)  
• Electrophysiology markers translate from clinical to preclinical research 
ABSTRACT   
Electrophysiology provides a real-time readout of neural functions and network capability in 
different brain states, on temporal (fractions of milliseconds) and spatial (micro, meso, and 
macro) scales unmet by other methodologies.  However, current international guidelines do not 
endorse the use of electroencephalographic (EEG)/magnetoencephalographic (MEG) 
biomarkers in clinical trials performed in patients with Alzheimer’s disease (AD), despite a 
surge in recent validated evidence. This Position Paper of the ISTAART Electrophysiology 
Professional Interest Area endorses consolidated and translational electrophysiological 
techniques applied to both experimental animal models of AD and patients, to probe the effects 
of AD neuropathology (i.e., brain amyloidosis, tauopathy, and neurodegeneration) on 
neurophysiological mechanisms underpinning neural excitation/inhibition and 
neurotransmission as well as brain network dynamics, synchronization, and functional 
connectivity reflecting thalamocortical and cortico-cortical residual capacity. Converging 
evidence shows relationships between abnormalities in EEG/MEG markers and cognitive 
deficits in groups of AD patients at different disease stages. The supporting evidence for the 
application of electrophysiology in AD clinical research as well as drug discovery pathways 
warrants an international initiative to include the use of EEG/MEG biomarkers in the main 
multicentric projects planned in AD patients, to produce conclusive findings challenging the 







The International Working Group (IWG) and the US National Institute on Aging–
Alzheimer’s Association (NIA-AA) have recently proposed and refined guidelines for the 
diagnosis and monitoring of Alzheimer’s disease (AD) at the preclinical, prodromal (with 
objective mild cognitive impairment (MCI) but with aut onomy substantially preserved), and 
overt dementia stages, based on in-vivo fluid and neuroimaging biomarkers (Dubois et al., 
2014; Jack et al., 2018). According to these diagnostic guidelines, AD status is associated with 
(1) a reduction of cerebrospinal (CSF) A42 and an increase in amyloid at the brain level as 
revealed by amyloid positron emission tomography (PET) mapping, and (2) an increase of 
phospho-tau in both CSF and tau PET mapping. Neurodegeneration may be revealed by 
Fluorodeoxyglucose PET (FDG-PET), total tau in CSF, and magnetic resonance imaging 
(MRI) of brain atrophy in temporoparietal cortex and the hippocampi.  
Whilst these methodologies capture relevant AD processes, their uses are limited in the 
general clinical setting due to cost and invasiveness, especially for serial recordings over time 
(Dubois et al., 2014). In this respect, electrophysiology offers a promising and practical 
alternative that is both non-invasive and cost-effective. Electrophysiology allows the 
investigation of neurophysiological mechanisms underlying neural ionic current flows and 
related voltages at different spatial scales in the brain at an insuperable time resolution (i.e. 
<1ms). 
Due to the huge amount of information embedded in the waves recorded as 
electrophysiological signals, and in the gray zone between signal and biological/instrumental 
noise, there are some uncertainties about how to choose the optimum electrophysiological 
markers to extract from the recorded signals for preclinical and clinical research in AD. 
Furthermore, there may be difficulties in choosing which of the markers to use in a study, 
because often several alternative electrophysiological markers could be informative for the 
same research purpose.  To overcome these uncertainties, several independent experts of 
cellular neurophysiology, translational and clinical neurophysiology, pharmaco-
electroencephalography (EEG), magnetoencephalography (MEG), mathematical modeling of 
complex phenomena, and AD biomarkers wrote the present White Paper to define approaches 
to maximize the potential of electrophysiology applications in AD research to inform both 
research, diagnostics, patient stratification, disease progression and clinical development. This 
Paper reports their cross-disciplinary, unanimous consensus and recommendations about 
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evidence-based opportunities and limitationss offered by several modern electrophysiological 
markers for preclinical and clinical AD research.  
 
2. ELECTROPHYSIOLOGY AND ALZHEIMER’S DISEASE (AD) 
 
2.1. Electrophysiology probes effects of Alzheimer’s disease (AD) on brain neural 
synchronization and functional connectivity at different spatial scales  
 
Electrophysiology can be applied to investigate effects of AD processes (i.e. 
amyloidosis and tauopathy) on two main neurophysiological mechanisms underpinning human 
sensorimotor and cognitive functions: (1) synchronization/desynchronization of neural 
activities (i.e., post-synaptic and action potentials), as revealed by electrophysiological signals 
recorded in two or more neurons at a given frequency and location, and (2) 
coupling/decoupling of neural activities, as revealed by electrophysiological signals recorded 
in two or more populations of neurons.  
These mechanisms can be investigated using electrophysiological techniques at 
different spatial scales providing extensive opportunity for integration and interpretation of 
translational information from experimental models to human subjects: (1) microscale (< 50 
m) for synaptic connections between pairs of neurons. Patch clamp is used to record ionic 
currents through the neural membrane while single unit recordings probe action and post-
synaptic potentials. Experimental challenges can include several amyloid and tau species and 
therapeutic candidates; (2) mesoscale (100 m < > 1 mm) for connections within and between 
circumscribed neural populations such as those organized within cortical minicolumns (50 m) 
and macrocolumns (< 1 mm). Intracerebral recordings reveal local field potentials (LFPs) in 
animal AD models; and (3) macroscale (> 1 mm) for connections between large neural 
populations as those organized within brain structures and regions. Intracerebral and epidural 
recordings collect LFPs and EEG activity in animal AD models, while extracranial recordings 
of EEG or MEG activity are collected in AD patients at different stages of the neuropathology. 
Figure 1 illustrates the spatial and temporal resolutions of the main electrophysiological 
techniques applied to preclinical and clinical AD research.  
LFPs and EEG/MEG activity differ in relation to the generating mechanisms. LFPs are 
produced by the synchronization of activity and generation of post-synaptic potentials in 
several squared millimeters of brain pyramidal neurons (Nunez, 2000). EEG/MEG activity is 
generated by the synchronization of activity and generation of post-synaptic potentials in 
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several squared centimeters of cortical pyramidal neurons. Of note, this synchronization is the 
output of the brain system generating LFPs and EEG/MEG activity (Nunez, 2000). Figure 2 
illustrates how the main electrophysiological techniques can probe brain neural 
synchronization and coupling in vitro and in vivo. 
General topological features of the functional connectivity between nodes of brain 
system generating LFPs and EEG/MEG activity can be explored by graph theory (Bullmore 
& Sporns, 2009). Some graph theory indices are information circulation, network robustness 
and adaptation to pathological disturbances, modularity and functional specialization of 
subnetworks, and “small-worldness” defined as a good balance between an intense local 
connectivity and effective “hubs” for the remote connectivity (Bullmore & Sporns, 2009). This 
approach may be quite relevant for characterizing AD as a “brain disconnection syndrome” 
(van Straaten & Stam, 2013). However, it still lacks an international consensus on several 
important procedural aspects such as spatial sampling of EEG/MEG activity, edge definition 
in connectivity, statistical thresholds for the determination of the existence of a connection, and 
how to deal with instrumental and/or biological noise in the data. These aspects should be well 
defined in future AD research (Vecchio et al., 2017; van Diessen et al., 2015; van Diessen et 
al., 2015; Smith and Escudero, 2017).  
 
2.2. Main features of electrophysiological signals 
 
Electrophysiological signals reveal unique neurophysiological dimensions of brain 
capacity and reserve in AD. These signals can be considered as reflections of outputs of neural 
systems regulating synchronization/desynchronization and functional coupling/decoupling in 
neural brain populations regulating vigilance, motivation, and cognitive processes (Nunez, 
2000; Nunez et al., 2015; Voytek and Knight, 2015). Inputs to these systems derive from 
several interdependent neural circuits including (1) ascending activating fibers from brainstem 
and basal forebrain; (2) thalamocortical, corticothalamic, and cortical local interneurons; and 
(3) cortico-cortical fibers ensuring longitudinal intra-hemispheric and inter-hemispherical 
(e.g., corpus callosum, commissures, etc.) neural transmissions (Nunez, 2000; Fields, 2008; 
Voytek and Knight, 2015). These circuits are important components of the subcortical white 
matter and convey electrochemical oscillatory signals that regulate functional connectivity and 
synchrony in the brain neural spiking activity (Fields, 2008; Nunez et al., 2015). Indeed, 
myelinization of ascending fibers affects the speed of action potentials across axons and, then, 
the synchrony of volleys of action potentials, neurotransmitter release, and postsynaptic 
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potentials at synapses within distributed cognitive systems underpinning mental operations, 
encoding-retrieval processes, learning, and executive functions (Nunez and Srinivasan, 2006; 
Nunez et al, 2015). Consequently, alterations in axon myelination and white matter integrity 
are associated with abnormalities in rsEEG rhythms and clinical manifestations (Voytek and 
Knight, 2015). For example, alterations in brain white matter and functional connectivity have 
been associated with abnormal rsEEG rhythms and cognitive processes in patients with 
schizophrenia, depression, Parkinson’s disease, and other pathological conditions (Fields, 
2008; Nunez et al., 2015; Voytek and Knight, 2015). 
The relationships between these outputs and inputs of neural systems can be represented 
by values in the space of deterministic-random (i.e., stochastic), complexity-simplicity, linear-
nonlinear, stationary-nonstationary, and phase-nonphase locking dimensions that may be 
differently affected by AD processes. These dimensions may be candidate biomarkers of AD. 
However, their neurophysiological interpretation should always consider the following 
confounding factors: (1) head volume conduction through the brain, skull and scalp, of a 
myriad of extracellular ionic currents and associated post-synaptic and action potentials 
generated by neural interactions for billions of neurons and hundreds of brain regions. This 
head volume conduction produces not only the summation of extracellular ionic currents and 
associated potentials, but also their partial or complete cancellation when they are opposite in 
the polarity; (2) biological noise produced by non-neuronal ionic currents or potentials (e.g., 
ocular, muscle, and cardiac activities); and (3) instrumental noise due to recording systems 
and environmental electromagnetic sources. See the Panel 1 for more details. 
 
3.  CLINICAL ELECTROPHYSIOLOGY OF AD 
Electrophysiology can be investigated in AD patients during a variety of experimental 
conditions including; sleep, quiet wakefulness, and during sensorimotor and cognitive events, 
and measurements can include spontaneous or triggered electrical activities permitting both 
investigation of general network activity and network responsiveness.  
When endogenous or exogenous events trigger sensorimotor and cognitive information 
processing, event-related and phase-locked changes of this EEG (MEG) activity can be 
investigated by two linear procedures: (1) event-related potentials (ERPs) or their magnetic 
counterpart (event-related magnetic fields, ERMFs) and (2) event-related oscillations (EROs) 
or their magnetic counterpart (event-related magnetic oscillations, ERMOs). A typical ERP 
paradigm for AD research is the “auditory oddball task” in which patients receive a sequence 
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of frequent (80% of probability) and rare (20%) stimuli with the request to respond with a hand 
movement or silent counting only to the rare ones (for a review see Rossini et al., 2006).  
Event-related and nonphase-locked changes of ongoing EEG (MEG) rhythms can be 
investigated by a linear procedure to produce the so-called event-related 
desynchronization/synchronization (ERD/ERS). More details on these paradigms are 




3.1. Resting state EEG/MEG rhythms in AD at the group level  
 
EEG 
Amplitude or source activity of resting state eyes-closed cortical EEG rhythms 
probes the mechanisms of synchronization/desynchronization of thalamocortical and 
ascending activity systems in the maintenance of low vigilance in quiet wakefulness and can 
unveil the progressive effects of AD and intervention on these systems at the group level, 
even at late disease stages (direct assessment of the patient’s cognitive skills is not required).  
As a reference, cognitively normal old (Nold) subjects show prominent amplitude 
or source activity of resting state cortical EEG (MEG) rhythms at alpha frequencies (8-12 
Hz) in posterior regions and low amplitude of spatially widespread delta (< 4 Hz) and theta 
(4-7 Hz) rhythms. Compared to Nold subjects, Alzheimer’s Disease with Dementia (ADD) 
groups typically exhibit an increase of delta/theta rhythms and a decrease of alpha and beta 
(14-30 Hz) rhythms (Jelic et al., 2000; Brassen and Adler, 2003; Onofrj et al., 2003; Jeong, 
2004). Compared with dementia due to Parkinson’s Disease Dementia (PDD) and Lewy 
Body diseases (LBD), ADD groups are characterized by abnormally lower posterior alpha 
and less disruption of delta rhythms (Babiloni et al., 2017a).  
Interrelatedness (e.g., spectral coherence) of EEG (MEG) rhythms at different scalp 
sensors or cortical sources probes the progressive effects of ADD and intervention on the 
mechanisms of coupling/decoupling of synchronization in thalamocortical and cortical 
neural activity. This approach is insightful as cognition is strictly related to synchronous 
patterns of activation in brain neural networks, regulated by neurophysiological oscillatory 
mechanisms (e.g., visual, spatial, somatosensory, and semantic contents of our mental 
images or thoughts). However, two caveats should be emphasized in the interpretation of the 
results. Computing the interrelatedness of EEG (MEG) cortical sources, using estimates of 
functional cortical connectivity in the maintenance of low vigilance, involves some 
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mathematical assumptions, so different solutions correspond to different assumptions. 
Furthermore, whether interrelatedness (e.g., spectral coherence) of EEG (MEG) rhythms 
between EEG sensors can reliably reflect that functional cortical connectivity is an open 
issue.  
Clinical findings in ADD patients have revealed abnormally reduced spectral 
coherence in alpha and beta (13-20 Hz) rhythms between posterior electrode pairs at the group 
level (Jelic et al., 2000; Jeong et al., 2004). Alternative techniques sensitive to both linear and 
nonlinear interrelatedness (e.g., synchronization likelihood, phase lag index, directed transfer 
function, linear lagged connectivity, etc.) may cross-validate topography of the effects, while 
source analysis localizes them at intrahemispherical and inter-hemispherical levels (Babiloni 
et al., 2016b, 2017; Stam et al., 2007; Blinowska et al., 2017). More variable and less reliable 
are those readouts at delta and theta coherences (Knott et al., 2000), possibly due to the 
complex topographical pattern of the effects.  
For applications in intervention clinical trials, deterioration of EEG rhythms can be 
longitudinally investigated over time (e.g. about 12-24 months) in groups of MCI and ADD 
subjects and there is a body of existing evidence permitting predicted outcomes of an 
efficacious therapeutic on the electrophysiological read outs: (1) increased delta-theta and 
decreased alpha-beta rhythms at parieto-occipital electrodes (Coben et al., 1985); (2) 
increased theta and decreased beta rhythms at temporal and temporooccipital electrodes (Jelic 
et al., 2000); and (3) increased delta and decreased alpha 1 in parieto-occipital sources 
(Babiloni et al., 2014b). Approved symptomatic treatments, e.g. Acetylcholinesterase 
inhibitor drugs (i.e. enhancing the cholinergic tone) showed a reduction in deterioration of 
delta  (Balkan et al., 2003; Gianotti et al., 2008), theta (Adler et al., 2004; Gianotti et al., 
2008), and alpha frequency rhythms over time (Balkan et al., 2003). If beneficial effects are 
observed in short-term studies, they may predict longer-term therapeutic efficacy (Adler et 
al., 2004; Babiloni et al., 2013), although as the effects reported in these studies have been 
mixed, additional investigation is necessary.  
Of note, the mentioned EEG biomarkers have been validated in ADD patients with 
other established biomarkers including, cortical blood hypoperfusion and synaptic dysfunction 
and atrophy in the posterior cortex (Fernandez et al., 2003; Babiloni et al., 2015) revealed by 





The mentioned EEG biomarkers at the group level were cross-validated using high-
resolution MEG techniques. Compared to Nold subjects, ADD and MCI groups showed an 
increase of delta/theta rhythms and a decrease of alpha rhythms (Fernández et al., 2006a), more 
pronounced in the former than the latter. Compared to monodomain (amnesic) MCI, 
multidomain MCI patients showed more similarities with the ADD group (López et al., 2014). 
Furthermore, MCI patients with higher delta rhythms had greater risk of progressing to 
dementia (López et al., 2014). Moreover, both single and multiple-domain MCI groups 
exhibited a decreased functional connectivity affecting medial temporal and parietal regions 
within alpha and beta frequency bands (Cuesta et al., 2015). At the brain connectome level, 
combined MRI and MEG techniques in prodromal AD patients unveiled both structural 
disconnection and derangement of alpha rhythms in the default mode network (DMN) 
involving posterior cingulate, precuneus, angular gyrus, and medial prefrontal cortex (Garcés 
et al., 2014). Furthermore, MCI patients with abnormal CSF p-tau and Aβ42 levels compared 
with controls (i.e. MCI patients with normal CSF markers) exhibited abnormal functional 
connectivity among limbic structures such as the anterior/posterior cingulate cortex, 
orbitofrontal cortex, and medial temporal areas in different frequency bands (Canuet et al., 
2015). Moreover, they exhibited a reduction in posterior cingulate functional connectivity 
mediated by p-tau, associated with impaired axonal integrity of the hippocampal cingulum 
(Canuet et al., 2015). Finally, cognitively normal older adults positive to amyloid PET 
diagnostic markers of AD showed an abnormal functional connectivity of the precuneus 
(Nakamura et al., 2017). 
Another validation of MEG techniques concerned nonlinear and complex features of 
neural systems generating brain rhythms in AD. Lempel-Ziv complexity and approximate 
entropy markers unveiled reduced entropy and complexity in MEG rhythms in groups of ADD 
patients compared with MCI and Nold subjects (Fernández et al., 2010; Azami et al., 2017).  
 
3.2. Resting state EEG/MEG rhythms in AD at the individual level 
 
EEG 
Stratification of ADD and MCI individuals is an important step in observational (e.g., 
prevention studies) and intervention clinical trials. An exciting research line may test this 
biomarker feature on amplitude or source activity of resting state (eyes-closed) cortical EEG 
rhythms. A bulk of existing evidence highlights the under-utilised power of EEG information 
in dementia patient stratification and warrants further investment to fully validate these 
applications for clinical utility. Global delta and alpha coherences between electrode pairs 
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successfully classified ADD compared with DLB people with an accuracy of 75-80%. 
Combined EEG power density and coherence reached 90% in the discrimination of ADD vs. 
Nold and ADD vs. PDD subjects (Engedal et al., 2015). A similar approach reached a 
classification accuracy of 100% in small populations of ADD, PDD/DLB, and 
frontotemporal dementia patients.  
A clinical study combining EEG data with neuropsychological, clinical, 
neuroimaging, cerebrospinal fluid, and visual readouts of EEG data permitted a classification 
accuracy of 87% in the discrimination between ADD, PDD, and DLB (Dauwan et al., 
2016b). Furthermore, a combination of linear and nonlinear measures of interdependence of 
rsEEG rhythms reached a classification accuracy of 80-85% in the discrimination of Nold 
and MCI individuals (Dauwels et al., 2011). A classification accuracy around 80% is reached 
using cortical EEG source estimates in the discrimination between Nold subjects vs. 
ADD/DLB/PDD patients and ADD vs. PDD patients with an accuracy of 85-90% (Babiloni 
et al., 2017). Such accuracy drops under 80% in the classification of individuals with 
prodromal stages of those dementing disorders (Babiloni et al., 2017). 
Another interesting clinical effort should focus on testing the predictive value of EEG 
biomarkers at about 6-24 months. Previous studies have showed encouraging results with 
the following variables: (1) combined alpha-theta power density and mean frequency from 
left temporal-occipital regions (Jelic et al., 2000); (2) anterior localization of alpha sources 
(Huang et al., 2000); (3) high temporal delta sources (Rossini et al., 2006); (4) high theta 
power density; and (5) low posterior alpha power density (Luckhaus et al., 2008).  
 
MEG 
Again, the mentioned EEG biomarkers at the individual level were cross-validated 
using high-resolution MEG techniques. A seminal MEG study showed that augmented delta 
activity in posterior parietal and precuneus cortices was negatively correlated with cognitive 
status and distinguished with classification accuracy > 80%, 23 MCI patients from 35 AD 
patients with different severity scores and 24 controls (Fernández et al., 2013).  
In other exploratory MEG studies carried out in small groups of ADD vs. Nold 
individuals (e.g. mostly around 20 subjects for group), nonlinear estimates reached accuracies 
of about 80-87% (Gómez et al., 2009). Furthermore, Lempel-Ziv complexity estimates 
combined with age reached accuracies of about 95% in the discrimination between ADD and 
MCI individuals with less success between Nold and MCI ones (Fernández et al., 2010). In 
another trial, entropy estimates reached accuracies of 83.9% and 65.9% in the discrimination 
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of ADD and MCI subjects from Nold subjects, respectively (Bruña et al., 2012). These 
preliminary MEG results on at risk populations were challenged in a study that compared 102 
MCI patients to 82 age-matched controls and found that mutual information and functional 
connectivity estimates reached a discriminative accuracy of 79-83% (Maestú et al., 2015). 
Other cross-validation research may relate resting state MEG readouts and AD 
physiopathological markers. Along this line, posterior MEG delta rhythms correlated with 
hippocampal atrophy, and a combination of rsMEG and MRI volumetric data allowed a correct 
classification of 87.1% (Fernández et al., 2003). In a first follow-up study, the estimated 
relative risk of conversion from MCI to ADD dementia was increased by 35% in those MCI 
patients with augmented posterior parietal delta activity (Fernández et al., 2006c). In a second 
follow-up study, a combination of left hippocampal volume, occipital cortex theta power, and 
clock drawing copy subtest scores predicted conversion from MCI to AD dementia with an 
accuracy of 97% (López et al., 2016). 
 
3.3. Event-related EEG/MEG activity in AD at the group level 
 
Amplitude or source activity of event-related EEG activity probes the mechanisms 
of synchronization/desynchronization and coupling/decoupling of thalamocortical and 
ascending activity systems during sensory and cognitive-motor information processes and 
can unveil the progressive effects of AD and intervention at the group level, especially at 
early disease stages. Previous evidence encourages investment in more clinical research in 
this area. Panel 3 provides more details on the typical experimental paradigms used in this 
research. 
In an auditory oddball task (i.e. ignore frequent stimuli, react to rare “target” stimuli) 
involving attention and short-term episodic memory, P50 amplitude following frequent 
stimuli (P = positive; peak at around +50 ms poststimulus) was greater in MCI compared 
with Nold subjects. It was also greater in multidomain/progressing than monodomain/stable 
MCI subjects (Golob et al., 2007). Furthermore, P300 amplitude following rare stimuli was 
smaller and its peak latency longer in MCI and ADD patients compared with Nold subjects, 
even across task difficulty and sensory modalities (Golob et al., 2007; Polich and Corey-
Bloom, 2005). The P300 has been shown sensitive to AD neuropathology (Morgan and 
Murphy, 2002), although its latency also increases over time (about 1-2 ms/year) in 
physiological aging (Iragui et al., 1993). 
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ERP components showed differences in Nold and ADD subjects during the analysis of 
(1) semantic/linguistic stimuli and (2) repeated words. In Nold subjects, parietotemporal N400 
is larger in amplitude in response to meaningful stimuli that are semantically incongruous, 
regardless of stimulus type (words vs. images) and types of mismatch (semantic vs. 
phonological; Kutas and Federmeier, 2011). This effect is linked to semantic memory and 
differs from the mid-frontal N400 (FN400) related to familiarity-related memory processes 
(Rugg and Curran, 2007). Physiological aging reduces the modulation of N400 by semantic 
incongruity, but less than in pathological aging; indeed, both above factors modulating N400 
were reduced or abolished in AD patients with mild dementia (Olichney et al., 2006).  
In healthy subjects, ERP data also exhibit a significant word repetition effect for both 
incongruous and congruous words, namely an attenuation of their amplitude. Noteworthy, the 
attenuation of the N400 for the repetition of incongruous words was poor in MCI compared 
with Nold subjects (Olichney et al., 2002) and predicted subsequent progression to AD 
dementia. Such observations largely applied across modalities, make N400 a promising 
biomarker to assess disease severity and progression (Olichney et al., 2011).  In the same line, 
the attenuation of a widespread posterior P600 for the repetition of congruous words was poor 
in AD patients with mild dementia compared with Nold subjects (Olichney et al., 2006) and 
predicted subsequent progression from MCI to AD dementia. 
ERP components also point to differences in Nold and AD subjects during episodic 
memory tasks. In healthy subjects, the P600 is a late positive component (LPC) observed 
during both memory encoding and retrieval (recall or recognition) of words. The P600 
amplitude normally increases for previously presented words (“old” words) successfully 
retrieved, while it decreases when words are repeated in a predictable, fixed context. Previous 
studies with ADD and MCI patients revealed that the P600 repetition effect is greatly reduced 
or absent in ADD and present but delayed in MCI non-converters (Olichney et al., 2002). It 
can be speculated that early detection or diagnosis of AD may be enhanced by including 
semantically congruous and incongruous word pairings within a repetition paradigm, allowing 
assessment of P600 as well as N400. 
The above “cognitive” ERP components and others were also able to predict AD 
progression over time at the group level. Compared with Nold or stable MCI over time, 
progressing-to-dementia MCI showed increased P50 and N100 amplitude, decreased N200 
amplitude (Papaliagkas et al., 2011), increased N200 latency (Missonier, 2007), increased P300 
latency (Lai et al., 2010), decreased N400 and P600 (Olichney et al., 2002), and decreased 
mismatch negativity (MMN) reflecting the automatic detection of changes in the acoustic 
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environment (Lindin et al., 2013). Furthermore, pre-symptomatic autopsy-proven older adults 
(Olichney et al., 2013) and AD mutation carriers (Golob et al., 2009) exhibited reduced N400 
to semantic processing (Bobes et al., 2010) and an abnormal topography of P200-P300 (Quiroz 
et al., 2011) during episodic memory almost 10 years prior to clinical presentation. 
The above “cognitive” ERP components monitored AD progression over time at the 
group level. In longitudinal studies, MCI and ADD patients (untreated with cholinergic 
therapy) showed changes over time in the MMN, P300, N400, and P600 (Lindin et al., 2013; 
Papaliagkas et al., 2011).   
ERPs were also sensitive to cholinergic therapy (Donepezil or Rivastigmine) in ADD 
patients, after both short (days/few weeks) and longer periods (3 months-1 year). Specifically, 
the beneficial effects of the treatment on brain function were mainly observed as a reduction 
of auditory P300 peak latencies that related to an improvement on cognitive tests (Onofrj et al., 
2003).   
EROs were repeatedly investigated in oddball tasks. Frontal delta EROs responses 
(visual and auditory) were attenuated in ADD patients compared with Nold subjects (Yener et 
al., 2007). Also, theta EROs showed lower frontal phase-locking values in the former than the 
latter (Güntekin et al., 2008). This effect was less evident or negligible when visual and 
auditory stimuli were given with no task requested (Yener et al., 2013). EROs were also 
sensitive to AD progression over time and cholinergic therapy.  Progressing-to-dementia MCI 
patients showed lower theta and beta EROs compared with stable MCI patients (Missonier et 
al., 2007; Jiang et al., 2015; Hedges et al 2016). In cross-sectional studies, EROs in oddball 
task demands showed higher frontal theta phase-locking across repeated events (Yener et al., 
2007)  and greater fronto-parietal alpha coherences in ADD patients treated with AChEIs 
compared with non-treated ones (Güntekin et al., 2008). With simple visual stimuli with no 
task, EROs showed improved posterior theta responses in ADD patients treated with AChEIs 
compared with non-treated ones. 
Event-related EEG rhythms were also investigated using a cross-modal episodic 
memory task. Differences were observed in EEG complexity between untreated ADD and 
control groups over multiple time scales during task execution (Morison et al., 2013).  
Event-related EEG biomarkers have been cross-validated using high-resolution MEG 
techniques. Compared with Nold subjects, MCI patients showed significantly higher occipital, 
temporal, and frontal ventral ERMFs during a short-term memory task (Maestú et al., 2008). 
Furthermore, MCI patients showing significantly higher memory task-related alpha and beta 
rhythms in a ventral cortical pathway, converted more rapidly to AD dementia (Bajo et al., 
15 
 
2012a). When such augmented MEG activity was explored using a functional connectivity 
approach, MCI patients exhibited an increased marker of prefrontal and long-range functional 
connectivity from alpha to gamma bands (Bajo et al., 2010). Finally, another MEG study 
pointed to a reduction in the complexity of functional networks involved in memory-related 
changes (Sternberg task) of widespread theta and alpha rhythms (Ahmadlou et al., 2014).  
 
3.4. Event-related EEG/MEG biomarkers of AD at the individual level  
 
Stratification of ADD and MCI individuals in observational and intervention clinical 
trials may be based on event-related EEG/MEG biomarkers. A recent study showed that the 
MMN amplitude successfully discriminated aMCI and Nold individuals with a classification 
accuracy of 75% (Lindin et al., 2013). 
In the prodromal stage of AD, a reduced word repetition effect on the P600 
discriminated MCI subjects who converted to dementia compared with “stable” MCI subjects 
with a classification accuracy of 85% (Olichney et al., 2002). In another study, oddball P300 
latency allowed prediction to AD dementia with an accuracy of 65% in subjects with subjective 
memory complaints (Gironell et al., 2005). Analogously, auditory N200 resulted in a 
classification accuracy of 91% in the prediction of MCI patients that converted to ADD within 
the follow-up at 5 years (Papaliagkas et al., 2008). Furthermore, ERPs (including the P300) 
accompanying a number-letter paradigm, which employed a visual task with memory and 
other cognitive demands, predicted the progression to AD dementia with an accuracy of 70-
78% in MCI subjects (Chapman et al., 2011).  
Oddball parietal delta EROs reached a classification accuracy of 76% in the 
discrimination of ADD patients vs. Nold subjects (Polikar et al., 2007).  
Other ERP components exhibited an interesting prediction value. In MCI subjects, 
P200 and N200 ERP latencies as well as EROs recorded during attention and memory demands 
predicted cognitive decline after 1 year with an accuracy of 93%, 78%, and 72%, respectively 
(Missonnier et al., 2007). The combination of the three EEG markers correctly predicted the 
outcome of 90% of MCI cases.  
An approach based on permutation entropy in MEG reached an accuracy of 98.4% in 
the classification of 18 MCI vs. 19 Nold controls using MEG activity related to working 
memory as an input to a probabilistic network classifier (Amezquita-Sanchez et al., 2016).  
 




It is well known that sleep plays a crucial role in the processes of learning and memory, 
so sleep EEG biomarkers are of great interest in AD research. Converging evidence shows that 
non-rapid eye movement (NREM) stages of sleep are affected by AD processes.  In ADD 
patients, EEG rhythms are characterized by excessive sleep fragmentation (Yulug et al., 2017), 
associated with a decrease in slow-waves in NREM sleep stages. In those NREM stages, ADD 
patients showed a significant (>40%) reduction in K-complex density over the frontal areas, 
correlated with their cognitive involvement (De et al., 2017). Furthermore, total frontal EEG 
slow-wave activity predicted reduced cerebrospinal (CSF) Aβ1-42 levels in preclinical AD 
subjects, when controlling for age and ApoE status (Varga et al., 2016). Moreover, sleep 
spindles were reported to decrease in ADD patients. More recently, a significant decrease in 
parietal fast spindle density was also reported in ADD and MCI patients, and this correlated 
with cognitive performance (Gorgoni et al., 2016). Finally, MCI and ADD patients showed 
poor Cyclic Alternating Pattern in non-REM sleep (CAP; Parrino et al., 2012; Ferri et al., 
2008), as a general difficulty to produce synchronized EEG slow waves underlying 
neuroplasticity during sleep (Maestri et al., 2015).   
 
4. BACK-TRANSLATION TO PRECLINICAL ELECTROPHYSIOLOGY 
Out of the 244 compounds (413 clinical trials) developed for AD between 2002 and 
2012, only one (0.4%) was approved (Cummings et al., 2014). Therefore, there is a dramatic 
need for high-construct validity in vivo efficacy assays and functional in vivo biomarkers in 
rodent models of AD as well as in vitro systems that fill the void of back-translational validity 
(Walsh et al., 2017). For this purpose, electrophysiology has ideal features with highly stratified 
spatial (from micro to macroscale) and millisecond temporal resolution (Booth et al., 2016; 
Drinkenburg, 2015; Jyoti et al., 2015; Scott et al., 2016). Electrophysiological readouts can be 
more readily interpreted in terms of functional relevance of the (compromised) brain in its full 
complexity (Palop and Mucke, 2016; Walsh et al., 2017).  
 
4.1. Electrophysiology in neuronal cultures  
 
Neurons isolated from rodent brains and cultured in vitro give insights into how disease 
pathology impacts the intrinsic functional output of a neuron or a simple network and can 
provide meaningful insights into more complex hierarchical systems. Cellular changes in 
activity can often be extrapolated up to those seen in vivo or in patients and can be recorded 
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using single electrodes to look at single cell activity or multielectrode arrays (MEAs) to observe 
networks. Neurons have an intrinsic necessity to network to survive in vivo and isolated 
neurons in culture will connect to each other and become synaptically networked with 
synchronised activity in a matter of days in vitro. Neurotoxic species such as synthetic peptides 
(commonly oligomeric A), cell-derived, and human brain-derived material can be 
successfully used in probing the effect of AD-relevant toxic species on electrophysiological 
activity of neuronal cultures at spatial microscales using single or multielectrode recordings. 
Synthetic aggregated A oligomers robustly alter neuronal excitability and survival and can be 
recorded with patch clamp techniques (Ferreira et al., 2011) but  human AD brain-derived A 
is more potent and has electrophysiological consequences at more physiologically relevant 
concentrations, but is more methodologically challenging due to the isolation of specific A 
fractions (Shankar et al., 2008).  
It is also possible to generate primary neuronal cultures from transgenic animals 
overexpressing A or Tau whose neurons also display increased intrinsic neural excitability 
associated with AD-relevant pathological challenges (e.g. Sanchez et al., 2012).  Synaptic 
changes are observed in culture and in-vivo but there is no proteinopathy in 2D culture.Tau 
seeding models can be used to mimic the neurodegenerative AD process more closely (Peeraer 
et al., 2015).  Newer, three dimensional cultures where neurons are embedded in a 3D matrix 
or cultured in spheroids do show more realistic pathological aggregations including both 
intracellular tau tangles and extracellular amyloid plaques (reviewed in D’Avanzo et al, 2015), 
however the functional analysis of these cultures using electrophysiology remains to be 
reported and may be more complex due to difficulty in accessing cells through the matrix.   
Most contemporary AD genetic models are mice carrying a human amyloid precursor protein 
(hAPP) mutation (usually APPswe) alone or in combination with presenilin-1 (PS-1) mutation 
and/or neurofibrillary tangles generated by expression of human MAPT (Onos et al., 2016). 
APP/(PS1) mice show human AD-like amyloid plaques in the cortex and hippocampus, and 
age-related memory impairment, but no neuronal loss unless several mutations are combined 
as in a so-called 5xFAD mouse model (Oakley et al., 2006). They may also show synaptic loss 
correlative with neurodegenerative processes (Mucke and Selkoe, 2012). More recently 
developed knock-in transgenic mouse models are considered a closer model of AD pathology 
since they do not over-express APP (Zhang et al., 2016). However, no transgenic AD mouse 
model reproduces all main pathophysiological (i.e., A or tau) and progressive cognitive and 
behavioral deficits like AD patients (reviewed in Gotz et al., 2008). Furthermore, these strains 
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can be considered as models of pre-symptomatic to mild AD. Beyond them, new transgenic rat 
models or intraventricular/intracerebral Aβ infusion in wild type rodents can be considered for 
AD electrophysiological research (e.g., Do Carmo and Cuello, 2013). Until very recently, 
studies of human neurons have been limited to immortal cell lines (e.g. SY-5Y neuroblastoma 
lines). They can be differentiated into more neuron-like cells and are very useful for studying 
the integrity of cholinergic activity, as well as testing compounds on cholinergic currents; 
however, they lack some intrinsic functional capabilities of primary neurons (Kar et al., 2004).  
Recent advances in induced pluripotent stem cell (iPSC) technology make it possible to 
perform living human neuronal studies in a dish (Takahashi et al., 2007). Differentiation 
protocols can generate over 50 different types of neurons and glia cells relevant for human 
disease modeling and hypothesis testing (Taber and Studer, 2014) as a function of genotyping 
and phenotypes (Mertens, et al 2015).  Human neurons can be studied using similar approaches 
to the rodent neuronal study methods outlined.  
These cell culture methodologies provide practical screening opportunities for 
pharmacological agents that can modify functional deficits driven by pathology in vitro.  
 
4.2. Electrophysiology in brain slices  
 
Promising preclinical AD research can be performed by recording electrophysiological 
signals from acute brain slices with locally intact neuronal networks formed by endogenous 
cells and functional connections in specific brain regions in isolation without ‘noise’ due to 
other complex connections. This approach allows mechanistic probing studies of 
pharmacological agents and also cellular communication between neurons and the brain’s other 
resident immune cells, including glia and microglia.  The effects of Aβ42 species on microglia 
(but not infiltrating monocytes) have been studied in this system (Villegas-Llerena et al., 2016). 
Acute brain slices (e.g., from hippocampus and cortex) can be derived from: (1) wild 
type rodents challenged with acute application of Aβ42, tau, modulatory neurotransmitters (e.g. 
Acetylcholine, glutamate) or therapeutic agents by intraventricular/intracerebral injections 
(e.g. Xu et al 2016) or (2) transgenic AD mouse models at different ages and stages of the 
pathology. Analysis may focus on effects of those agents on resting membrane potential, firing 
frequency and after-hyperpolarization magnitude, neural hyperexcitability, synaptic plasticity 
including long-term potentiation (LTP) and depression (LTD), and many cognitively relevant 
network oscillations at beta (20-30 Hz) and gamma (30-80 Hz) frequencies (e.g. Hazra et al., 
2013; Tamagnini et al., 2015). Expected results should reveal progressive impairment in neural 
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synchronization and functional connectivity in hippocampal and cortical networks with 
reduced LTP and beta (20-30 Hz) and gamma (30-80 Hz) frequency oscillations (Driver et al 
2007). However, some studies suggest caution as Aβ monomer/oligomer distribution in a given 
slice can reveal strongly variable deficits in LTP (Rammes et al., 2011). Furthermore, in-vivo 
mouse AD models showed mixed results concerning the reduction of those beta and gamma 
rhythms, possibly in relation to brain regions of interest, age, strain, and disease progression 
(Gurevisius et al., 2013, Papazoglou et al., 2016). 
Another promising preclinical assay for AD research utilises the Utah array to record 
electrophysiological signals to map changes in synchronization in longer-range interactions 
e.g. CA3 to CA1 in the hippocampus, or between deep and superficial layers in the cortex in 
slices (e.g. Ainsworth et al., 2016). Current source density analysis can reveal changes in brain 
neural synchronization while Granger analysis can determine interregional directional 
functional coupling/decoupling within recording contacts in a brain slice (Parsons et al., 2007).  
 
4.3. Electrophysiology in freely behaving rodents  
 
In behaving rodent AD models, abnormal electrophysiological brain activity (including 
ERPs and sleep) can be successfully recorded at the spatial mesoscale and macroscale by single 
neuron activity and LFP/EEG, respectively (Drinkenburg 2015; Scott et al., 2016). This 
approach has an obvious special “back-translational” value with reference to AD clinical 
symptoms (Palop and Mucke, 2016; Walsh et al., 2017). Even with the mentioned limitations 
of transgenic rodents (Drummond and Wisniewski, 2017), these animal models allow 
investigation of the direct relationship between AD neuropathology (progression) and its 
neurophysiological effects on brain neural networks (Drinkenburg et al., 2016; Palop and 
Mucke, 2016). Furthermore, although few studies have been published that use EP/ERP 
paradigms in AD rodent models (Gurevicius et al., 2013; Takahashi, 2013; Laursen et al., 2014; 
Drinkenburg et al., 2016; Zhang et al., 2016; Walsh et al., 2017), preclinical validation of the 
such paradigms is well established and they can be reliably used (Drinkenburg et al., 2016; 
Leiser et al., 2011).  
Keeping in mind this premise, a primary electrophysiological research line may clarify 
effects of Aβ on brain rhythms in AD rodent models. Indeed, hippocampal theta phase–gamma 
amplitude coupling was reduced in Aβ-overproducing 5XFAD transgenic mice and TgF344-
AD transgenic rats (Stoiljkovic et al., 2017). Furthermore, APP23 × PS45 mice showed a 
severely disrupted coherence of calcium transients and LFPs as an impairment of cortical 
20 
 
functional connectivity (Busche et al., 2015). Moreover, coherence and cross-frequency 
coupling at theta-gamma rhythms characterized AD processes in rodents (Ahnaou et al., 2014; 
Fries 2015; Palop and Mucke, 2016; Walsh et al., 2017) and the effects of a beneficial 
intervention in Aβ-overproducing 5XFAD mice (Iaccarino et al., 2016).  
Another important electrophysiological research line may characterize firing and 
oscillatory activities of hippocampal pyramidal neurons in transgenic AD mouse models in 
relation to learning and plasticity (Cayzac et al., 2015). In this line, normal hippocampal LTP 
induction but accelerated decay was found in freely moving aged APP/PS1 mice with robust 
brain amyloidosis (Gureviciene et al., 2004). Furthermore, human Aß selectively disrupted 
hippocampal LTP induction before amyloid plaque formation in McGill-R-Thy1-APP 
transgenic rats (Qi and co-workers, 2014). It also altered oscillatory responses to high-
frequency stimulation (Kalweit et al., 2015). In the same line, no changes in hippocampal theta 
oscillations were found in freely moving APP/PS1 mice before significant amyloid plaque 
formation (Gurevicius et al., 2013). 
Another electrophysiological research line may enhance our understanding of 
molecular and cellular mechanisms of AD-related enhanced excitability in rodents 
(Minkeviciene et al., 2009; Gurevicius et al., 2013; Palop and Mucke, 2016; Siwek et al., 2015) 
and the relative optimal anti-epileptic treatment (Ziyatdinova et al., 2011; Rong, 2016). Indeed, 
APP (Palop et al., 2007), APP/PS1 (Minkeviciene et al., 2009) and tau (Garcia-Cabrero et al., 
2013) transgenic mice display frequent epileptic seizures (Born et al., 2015; Subota et al., 
2017). In addition, focal epileptic or epileptiform activity in those mice may account not only 
for cognitive deficits (Palop and Mucke, 2010) but might also relate to early amyloid 
accumulation (Bero et al., 2011) and trans-synaptic spread of tau pathology (Yamada et al., 
2014).  
    This preclinical research line has remarkable translational value. A bulk of evidence 
has shown an increased risk of overt epileptic seizures or subclinical, non-convulsive, 
epileptiform-like EEG signatures in AD patients with fast clinical deterioration over time when 
compared to controls (Horváth et al., 2016; Vossel et al., 2016). Furthermore, convulsive 
seizures are 10 times more frequent in AD patients than the general population (Horváth et al., 
2016), while epilepsy is 87 times more frequent in AD patients with early than the late-onset 
disease (Scarmeas et al., 2009). Moreover, cognitive disorders appear 5.5 years earlier in AD 
patients with epileptiform discharges than AD controls (Vossel et al., 2013). Most of those 
discharges were observed during sleep, especially the non-rapid eye movement one (Horváth 
et al., 2017). 
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Panel 4 illustrates the most promising conditions of LFP/EEG recordings in freely 
behaving rodents.  
   
5. CONCLUDING RECOMMENDATIONS   
Electrophysiology is a multi-scale methodology suited to probing the effects of AD 
neuropathological processes (e.g. Aβ1-42, phospho tau, neurodegeneration of cholinergic 
systems, dysregulation of glutamate homeostasis) and disease-modifying drugs on 
synchronization/desynchronization and coupling/decoupling of brain neural activity in 
preclinical and clinical research.  
For preclinical AD research, we recommend the following methodologies: 
(1) At the microscale, in-vitro studies of membrane ionic currents and potentials at a single 
neuronal cell or slices of hippocampal tissue (Ferreira et al., 2011).  
(2) At the mesoscale, in-vivo LFP studies of synaptic dysfunction and neural overexcitation 
in transgenic rodent models complementing and cross-validating cell and slice 
electrophysiology studies (Drinkenburg et al., 2016; Palop and Mucke 2016; Walsh et 
al., 2017).  
(3) At the macroscale, in-vivo scalp and intracranial EEG/ERP studies of aberrant brain 
neural synchronization (e.g., increased risk of epilepsy) and functional thalamocortical 
and corticocortical connectivity as revealed by linear and nonlinear measures (Vossel 
et al., 2016; Horváth et al., 2017; Lam et al., 2017).  
The use of EEG in clinical AD research is impressive (see Table 1 in Supplementary 
material). Particularly abundant is the EEG/MEG research in patients with mild ADD during 
quiet wakefulness, which can be virtually developed in any hospital EEG lab in a non-invasive 
and cost-effective manner.  Novel, smart technologies emerging may also permit monitoring 
outside of the clinical setting soon. Relative topographical spectral (frequency domain) 
biomarkers may monitor the progression of the disease over years and therapy response. 
Indeed, this experimental condition is repeatable, noninvasive, and comparable during different 
stages of the disease and cognitive status.  
 
We also recommend EEG/MEG recordings and analysis (frequency and time domains) of 
data obtained in event-related paradigms in patients with preclinical and prodromal AD stages. 
Candidate biomarkers may be the reduction in frontal delta/theta and posterior alpha rhythms 
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and the amplitude decrease of the late positive potentials (e.g., oddball paradigm). Other 
promising candidate biomarkers probe reduction in functional cortical connectivity and 
complexity in several frequency bands at prodromal and dementia stages of the disease. Those 
candidate biomarkers might be used as “gatekeepers” for vast populations of seniors at risk of 
AD.  Necessary conditions for such use are their good sensitivity (> 80%) to prodromal or mild 
dementia stages of AD and consensus in international initiatives to overcome the current 
heterogeneity of methodological approaches for data recording and analysis. In addition, 
specificity as well as correlation with other biomarkers will thus have to be determined. 
Exemplary references for these future studies are (1) diagnostic guidelines of the IWG-2 for 
AD (Dubois et al., 2014), in particular the recommendations for diagnostic and topographical 
biomarkers and (2) international projects such as IMI PharmaCog (www.pharmacog.org), 
ADNI (http://www.adni.loni.usc.edu), and ENIGMA (http://www.enigma.ini.usc.edu).  
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Panel 1: Dimensions of electrophysiological signals 
Determinism - Randomness 
• Electrophysiological signals are deterministic when defined inputs to and parameters of neural sources 
of electrophysiological signals produce scalp rsEEG signals always showing the same characteristics.  
• Local field potentials (LFPs) and ongoing electroencephalographic (EEG) signals do not typically 
reflect a pure determinism. 
 
Simplicity – Complexity  
• Electrophysiological signals are generated by simple interactions into a neural system when they are 
predictable as features (i.e. electrophysiological signals recorded during motor reflexes or long-term 
potentiation).  
• These signals are generated by complex interactions into a neural system when some nodes of the 
network are unknown and electrophysiological signals are not predictable. LFPs and ongoing EEG 
signals do not typically reflect simple interactions. 
 
Linearity - Nonlinearity 
• Electrophysiological signals are linear when any linear combination of inputs to neural system 
generating those signals produces the same linear combination of them, each of which would have been 
produced in isolation by a given input. When that neural system operates as a random linear system, 
amplitudes and phases of each electrophysiological signal are expected to be independent of each other. 
• When electrophysiological signals are generated by a random nonlinear system, their amplitudes and 
frequencies may show harmonic relationships in the bispectrum and bicoherence. LFPs and ongoing 
EEG signals can show some nonlinearity in patients with epileptic seizures or several mental disorders. 
 
Stationarity - Nonstationarity 
• Electrophysiological signals are stationary when they show constant statistical features (e.g., mean, 
variance, and autocorrelation function, power spectra) over time. 
• The condition of stationarity or “quasi-stationary” can be found in electrophysiological signals for 
relatively short measurement periods of a few seconds. 
 
Phase - Nonphase locking 
• Electrophysiological signals are phase-locked when external (sensory stimuli) or endogenous 
(cognitive operations, motor acts) events change their phase.  





Panel 2: Experimental conditions of recordings of electroencephalographic (EEG) and 
magnetoencephalographic (MEG) signals in humans 
 
Resting state and sleep 
• EEG/MEG signals are recorded for few minutes during eyes-closed and -open conditions in quiet 
wakefulness to monitor brain vigilance systems or during the night to probe neurophysiological 
oscillations underpinning sleep.  
• EEG/MEG spectral analysis. Comparison of EEG spectral markers in relation to AD status and 
progression (control subjects as a reference).  
• Evaluation of slow waves and signs of overexcitability and epileptiform activity (e.g., spikes, waves, 
spike-waves).  
 
Evoked and Event-Related Potentials/Magnetic fields 
• EEG/MEG signals are recorded for some tens of minutes during repeated sensory stimuli (e.g., visual, 
auditory, etc.) with no response required in paradigms of evoked potentials (EPs) or magnetic fields 
(EMFs); 
• Those signals are recorded for some minutes during repeated sensory stimuli (e.g., visual, auditory, 
etc.) and some cognitive information processing and motor response in paradigms of event-related 
potentials (ERPs) or magnetic fields (ERMFs); 
• EEG/MEG signals associated with any single stimulus are averaged to produce ERPs/ERMFs, 
analyzed in the time domain as amplitude and latency of negative and positive peaks. 
 
Evoked and Event-Related Oscillations 
• Evoked/event-related oscillations (EROs) or their magnetic counterpart (event-related magnetic 
oscillations, ERMOs) probe the event-related and phase-locked changes of EEG (MEG) rhythms in the 
frequency domain. 
• EROs-ERMOs are obtained by (1) the FFT-based passband filtering of ERPs (ERMFs) accompanying 
rare stimuli. For this passband filtering, standard frequency bands are used, namely delta (< 4 Hz), 
theta (4-7 Hz), alpha (8-12 Hz), beta (13-30 Hz), and gamma (30-45 Hz); and (2) the measurement of 
the maximum amplitude from positive to negative peaks of the filtered ERPs at any electrode.  
• Event-related desynchronization/synchronization (ERD/ERS) of ongoing EEG (MEG) rhythms probe 
nonphase-locked reduction of alpha and beta power (ERD) as well as the increase of theta and gamma 




Panel 3: Event-related EEG/MEG paradigms for the exploration of neural basis of abnormal cognitive 
processes in AD 
 
Mismatch negativity (MMN) and oddball 
• In the pre-attentive MMN paradigm, EEG/MEG signals are recorded for some tens of minutes during 
repeated sensory stimuli (e.g., visual, auditory, etc.) with no response required while the subject is 
focused on another task (e.g. reading or watching videos); these stimuli are frequent (about 80%) or 
rare (20%) and presented in (pseudo)random order. 
• EEG/MEG signals associated with any single stimulus are averaged to produce ERPs/ERMFs and 
analyzed in the time domain as amplitude and latency of a frontal negative component peaking at about 
200 ms post-stimulus, the MMN. Those signals may be also analyzed in the frequency domain in the 
standard bands from delta to gamma. 
• In the attentive oddball paradigm, EEG/MEG signals are recorded for some tens of minutes during 
repeated sensory stimuli (e.g., visual, auditory, etc.); these stimuli are frequent (about 80%) or rare 
(20%), presented in (pseudo)random order and the subject has to respond only to the rare “target” 
stimuli (e.g. via counting or button press).   
• EEG/MEG signals associated with any single stimulus are averaged to produce ERPs/ERMFs and 
analyzed in the time domain mainly as amplitude and latency of a posterior positive component 
peaking at about 300 ms post-stimulus, the P300 or P3b. Those signals may be also analyzed in 
frequency domain in the standard bands from delta to gamma. 
 
N400/syntactic P600 
• In the semantic-incongruence N400 paradigm, EEG/MEG signals are recorded for some tens of 
minutes during couples of linguistic stimuli (e.g., visual, auditory, etc.) with no response required 
while the subject is focused on processing them; in some trials, the second stimulus is selected to 
produce an incongruity effect at either the semantic or phonological level.  
• EEG/MEG signals associated with the couples of stimuli are averaged to produce ERPs/ERMFs and 
analyzed in the time domain as amplitude and latency of negative peaks. The effect of semantic 
incongruence modulates a temporoparietal negative ERP peak at about + 400 ms poststimulus, the 
N400. Regardless of incongruence, a distinct mid-frontal N400 (FN400) is related instead to the 
repetition effect and familiarity-related memory processes. Hearing or reading grammatical errors and 
other syntactic anomalies also induces a modulation of a centro-parietal “syntactic” P600. 
• EEG/MEG signals associated with the couples of stimuli may be analyzed in the frequency domain in 
the standard bands from delta to gamma. 
 
Memory P600 
• In the episodic-memory P600 paradigm, EEG/MEG signals are recorded for some tens of minutes 
during sensory stimuli (e.g., words) during both a first encoding condition and, after a pause (usually 
between 1 minute and 1 hour), a second retrieval (recall or recognition) condition while the subject is 
focused on the stimuli. In the two conditions, the words produce an effect related to memory encoding 
or retrieval. In the retrieval condition, the subject usually responds with a “seen before” or “unseen 
before” decision.  
• EEG/MEG signals associated with the stimuli are averaged to produce ERPs/ERMFs and analyzed in 
the time domain as amplitude and latency of a late positive peak. In the retrieval condition, the effect 
of successful recognition modulates a positive (left) parietal ERP peak at about + 600 ms poststimulus, 
the P600.  
• EEG/MEG signals associated with the stimuli may be analyzed in the frequency domain at the standard 




Panel 4: Experimental conditions of recordings of local field potentials (LFPs) and 
electroencephalographic (EEG) signals in rodents 
 
Freely behaving 
• LFP/EEG signals are recorded for 24 hours (12 hours with light on and 12 hours of light off) to several 
days to monitor wake-sleep cycle, evolution of LFP/EEG frequency bands from 1 - > 100 Hz and 
behavioral activity and sleep structure over the day.  
• EEG spectral analysis (FFT, wavelet) combined with simultaneous video, accelerometer or 
electromyographic (EMG) recording. Segmentation of the recording into movement, waking 
immobility or more detailed sleep states. Comparison of EEG spectral markers in different behavioral 
states. Localization of LFP sources by silicon-based linear probes (Csicsvari et al., 2003) or distributed 
horizontal cortical electrode arrays (Lundt et al., 2016). Subcortical-cortical connectivity and the role 
of interneuron dysfunction (Gurevicius et al., 2013, Ahnaou et al., 2014). Combination of EEG or LFPs 
with in vivo calcium imaging (Busche et al.,2015) or optogenetics (Iaccarino et al., 2016). 
• Evaluation of overexcitability, epileptiform activity (e.g., spikes, waves, spike-waves) and epileptic 
seizures during wake-sleep cycle.  
 
Sensory and cognitive-motor processing 
• LFP/EEG signals are recorded for some minutes during repeated sensory (e.g., visual, auditory, etc.) 
stimuli with no response required in paradigms of evoked potentials (EPs); 
• LFP/EEG signals are recorded for some minutes during repeated sensory (e.g., visual, auditory, etc.) 
stimuli and some cognitive information processing and motor response are required in paradigms of 
event-related potentials (ERPs); 
• LFP/EEG signals associated with any single stimulus are averaged to produce ERPs or analyzed in the 
frequency domain to produce spectral markers at frequency bands of interest from 1 to > 100 Hz. 
Spectral markers include the computation of coherence or other indexes of functional coupling of 
LFP/EEG signals at electrode pairs. 
 
Long term potentiation (LTP) and depression (LTD) in anesthesia 
• LFP and single neuron signals are recorded from hippocampus during LTP/LTD paradigms in the full 
complexity of an intact brain. Such recordings are traditionally performed under general anesthesia to 
exclude movement and vigilance-related confounding factors. 
• Brainstem or hippocampal electrical stimulation to induce LTP and enhanced theta (4-8 Hz) 




Figure 1. Schematic overview of the scale of spatial and temporal resolution of measurement methods used for 
electrophysiology and functional neuroimaging. Measurement methods are electroencephalography (EEG), 
magnetoencephalography (MEG), near-infrared spectroscopy (NIRS), functional magnetic resonance imaging 
(fMRI), electrocorticography (ECOG), local field potential (LFP) recordings, micro-electrode array (MEA) 
recordings, and microelectrode (ME) recordings. Non-invasive methods are shown in blue and invasive methods 




Figure 2. Neural synchrony as a multiscale phenomenon. A | Local scale: within a small brain region or local 
network, at least three levels of analysis can be distinguished. a | Synchrony between single units in monkey area 
V1 stimulated by a drifting grating, as measured by a cross-correlogram. b | Local field potentials (LFPs) from 
eight recording electrodes in the suprasylvian gyrus of an awake cat. Maximum separation between electrodes 
was 7 mm. The overlapping traces show a brief episode of synchronization between the fast oscillations. c | 
Transient episodes of synchrony within a population of neurons recorded intracranially over the occipito-
temporal junction in an epileptic patient performing a visual discrimination task. Time-frequency analysis 
revealed an enhancement of the local energy in the gamma band around 300 ms following the visual stimulation. 
This enhancement corresponds to the transient synchronization of underlying populations. d | When recorded 
from a surface electrode, such synchronous patches appear as spatial summation of cortical responses that give 
rise to transient increases in the gamma band. B | Large scale: patches of local synchrony in distant brain sites 
can enter synchrony during cognitive tasks. Synchronous patterns between distant scalp electrodes were recorded 
in normal subjects engaged in a face recognition task. Black lines link electrodes that are synchronous during the 




Figure 3.  Putative neurophysiological models for the generation of “induced” nonphase-locked (ERD/ERS) and 
“evoked” phase-locked (ERP) changes in EEG (MEG) rhythms at the level of cortical pyramidal neurons in 
relation to a given event (i.e. stimulus, cognitive process, movement, etc.).  Note that both circuits (i.e. “induced” 
and “evoked”) are simultaneously active during the event and involve neurons of sensory organs, subcortical 
motor systems, activating ascending reticular system from brain stem, thalamocortical relay neurons (TCR), 
reticular thalamic nucleus (RE) neurons, and pyramidal neurons in the cerebral cortex. In these models, the 
nonphase-locked “induced” component of the EEG (MEG) signal might be due to prominent intrinsic 
thalamocortical and corticothalamic interactions modulated by input signals. In contrast, the phase-locked 
“evoked” component of the EEG (MEG) signal might be due to prominent inputs to thalamus and cerebral cortex. 
EEG (MEG) is generated by the spatial and temporal (synchronization) summation of the post-synaptic potentials 
in cortical pyramidal neurons. Adapted from Pfurtscheller and Lopes da Silva, Electroencephalography and 
Clinical Neurophysiology, 1999 (courtesy from the Publisher). 
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